Navigation Links
Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Date:10/12/2007

10 mg alone (placebo = 4.8/3.1 mm Hg). When compared to amlodipine 10 mg alone, AZOR 10/40 mg resulted in a 53 percent greater reduction in the mean change of systolic blood pressure.

IMPORTANT SAFETY INFORMATION ABOUT AZOR

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, AZOR should be discontinued as soon as possible. See WARNINGS AND PRECAUTIONS, Fetal/Neonatal Morbidity and Mortality.

In volume- and/or salt-depleted patients, symptomatic hypotension due particularly to the olmesartan component may occur after initiation of treatment with AZOR. Treatment should start under close medical supervision.

Patients, particularly those with severe obstructive coronary artery disease, may develop increased frequency, duration, or severity of angina or acute myocardial infarction on starting calcium channel blocker therapy.

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar effects would be expected with AZOR because of the olmesartan medoxomil component.

Since amlodipine is extensively metabolized by the liver and the plasma elimination half-life (t1/2) is 56 hours in patients with severely impaired hepatic function, caution should be exercised when administering AZOR to patients with severe hepatic impairment. The only adverse event that occurred in greater than or equal to 3% of patients treated with AZOR and more frequently than placebo was edema. The placebo-subtracted incidence was 5.7% (5/20mg), 6.2% (5/40mg), 13.3% (10/20mg), and 11.2% (10/40mg). The edema incidence for placebo was 12.3%.

Please see
'/>"/>

SOURCE Daiichi Sankyo, Inc.; Forest Laboratories
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
2. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
3. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
4. Northfield Laboratories Investor Update
5. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 26, 2014 A ... of the organ protrudes through the wall of a weak ... area at birth are some of the causes of hernias. ... hiatal, femoral, and incisional. An inguinal hernia is when part ... umbilical hernia is found in the area of the umbilicus. ...
(Date:11/26/2014)...  CARsgen, a leader in the development of Chimeric ... variety of cancers, today announced the completion of a ... China -based healthcare private equity fund.   ... development of new therapeutics for liver, lung, stomach and ... Shanghai Renji Hospital, the company plans to initiate clinical ...
(Date:11/26/2014)... The medical magnetic resonance imaging (MRI) ... with world market revenues for 2013 at $5.1 ... types of medical imaging have led to improvements ... conditions in children and adults, each imaging procedure ... Medical Imaging Markets , analyzes the current and ...
Breaking Medicine Technology:Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4CARsgen Completes Series A Financing 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... Meeting of the Heart Failure Society of America (HFSA) will ... recent studies relating to heart failure. Dr. D.J. ... a recent study of heart failure patients who are hospitalized ... the heart, and the heart is unable to manage the ...
... the following update for its range of advanced wound care ... regulatory approvals and product listings, Innocoll has added six more ... and spray formats that are available for commercialization in the ... Zealand. These products include:   CollaCare®, a ...
Cached Medicine Technology:Studying Fluid Overflow in Patients With Devices 2Studying Fluid Overflow in Patients With Devices 3Innocoll Provides an Update on its Range of Advanced Wound Care and Related Collagen-based Products 2
(Date:11/28/2014)... Melbourne, Australia (PRWEB) November 28, 2014 ... has undergone healthy growth over the past five ... population's increasing acceptance of therapies that are either ... conventional treatments. According to IBISWorld industry analyst David ... the ageing population and growing private health insurance ...
(Date:11/28/2014)... Kramer HealthDay Reporter , THURSDAY, ... the kitchen, through cooking classes or at home, may make ... recent review. Cooking programs and classes for children seem ... the new research. And, although the review didn,t look at ... programs might help children develop long-lasting healthy habits. ...
(Date:11/28/2014)... November 28, 2014 Mabel’s Labels ... kids lose® and an award-winning company established by four ... Cynthia Esp, and Tricia Mumby have been honored with ... recognized with the PROFIT Award for Excellence in Entrepreneurship. ... Esp, and Tricia Mumby) accepted the award on behalf ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Patten Pecans, ... locally grown. With those passions driving them, they've added ... Grown. Having tried other pecans oils, they've found this ... Georgia to be exceptionally flavorful, retaining the buttery pecan ... same nutritional benefits found in pecans nuts ...
(Date:11/28/2014)... Brentwood, TN (PRWEB) November 28, 2014 ... in Tennessee for the first time. PAI Medical Group ... M.D. will be performing a robotic hair transplant procedure ... at 9:00 A.M. , The first in Tennessee and ... PAI Medical Group now offers ARTAS robotic hair transplantation. ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2Health News:First in Tennessee - PAI Medical Group Announces ARTAS - The World’s Most Advanced Medical Robot Used for Hair Transplant Surgery 2
... from more emotional and behavioral difficulties when compared to ... the most when a parent is deployed overseas, according ... that having a parent deployed for a longer period ... struggled with emotional problems were important factors associated with ...
... , NEW ORLEANS and SUNNYVALE, Calif., Dec. ... interim results from a Phase I/II study showing safety and ... (NHL) treated with its HDAC inhibitor PCI-24781 as a single ... Annual Meeting being held in New Orleans, LA (Abstract # ...
... growth factor, researchers say , SUNDAY, Dec. 6 (HealthDay ... main tumor to other parts of the body is controlled ... a promising target for new drugs to prevent metastatic breast ... TGFb (transforming growth factor beta) regulates normal cell growth and ...
... NEW ORLEANS, Dec. 6 Sickle cell disease, a condition ... of the most common genetic blood disorders affecting millions of ... presented today at the 51st Annual Meeting of the American ... that the H1N1 pandemic presents for children with this blood ...
... ... Greater VA Healthcare System in West Los Angeles, will once again create a holiday party. ... and their families. , ... (PRWEB) December 6, 2009 -- Volunteer organizations and members of the community, in cooperation ...
... 5 , What: Cuts for a Cause ... fight against cancer and other terminal illnesses affecting children. All proceeds ... Children,s Research Hospital. Guests will enjoy complimentary beverages and hors d,oeuvres, ... Falls Church for all guests. Hoa Lai, a DJ known for ...
Cached Medicine News:Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 2Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 3Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 4Health News:Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting 5Health News:Breast Cancer's Spread Now Better Understood 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3
The 4mm diameter Revo suture anchor is designed primarily for arthroscopic and open rotator cuff repair. Additional applications include other shoulder repair procedures, as well as use in knees and ...
... fixation device offers superior fixation strength ... firmly reattaches soft tissue to the ... is indicated for the fixation of ... bone. The implant is composed of ...
... simple to use system can be used ... and is pre-packaged on a sterile disposable ... a simple and reproducible insertion of the ... Sliding (I.S.S.™) Eyelet Design allows for the ...
... is the smallest, strongest anchor on ... placement into even the smallest bones. ... or 4-0 ETHIBOND EXCEL suture with ... swaged needles. The kit includes a ...
Medicine Products: